Chen et al. report that high expression of IGFBP3 in castration-resistant prostate cancer is closely associated with disease progression, and LOX can inhibit the development of castration-resistant prostate cancer by suppressing IGFBP3 expression35. Here, IGFBP3 is linked to prostate carcinoma.